Difficulty: Medium
Average Score: 63%
Practice
A 34-year-old woman has irritable bowel syndrome with diarrhea that is not responsive to conventional therapies. Despite the small risk of severe constipation and ischemic colitis, the patient decides to begin therapy with granisetron, a drug that acts as a
Correct answer
A
Rationale
The correct answer is A) 5-HT3 receptor antagonist. Granisetron is a selective antagonist of the 5-HT3 receptor, commonly used to manage chemotherapy-induced nausea and vomiting. In this case, it can be prescribed off-label for irritable bowel syndrome with diarrhea due to its antiemetic properties and potential to reduce gastrointestinal motility.
Option B) 5-HT4 receptor agonist is incorrect because 5-HT4 agonists like tegaserod are used for IBS with constipation, not diarrhea. Option C) D2 receptor antagonist is incorrect as drugs like metoclopramide are D2 antagonists and mainly used for gastric motility disorders like gastroparesis. Option D) Muscarinic receptor antagonist is incorrect as drugs like hyoscyamine are used to treat symptoms of IBS but do not target 5-HT3 receptors.
Educationally, understanding the mechanisms of action of drugs affecting the gastrointestinal system is crucial for making informed treatment decisions. Knowing the specific receptor targets and their roles in different GI conditions helps tailor therapy to individual patient needs, improving treatment outcomes and minimizing side effects.
Option B) 5-HT4 receptor agonist is incorrect because 5-HT4 agonists like tegaserod are used for IBS with constipation, not diarrhea. Option C) D2 receptor antagonist is incorrect as drugs like metoclopramide are D2 antagonists and mainly used for gastric motility disorders like gastroparesis. Option D) Muscarinic receptor antagonist is incorrect as drugs like hyoscyamine are used to treat symptoms of IBS but do not target 5-HT3 receptors.
Educationally, understanding the mechanisms of action of drugs affecting the gastrointestinal system is crucial for making informed treatment decisions. Knowing the specific receptor targets and their roles in different GI conditions helps tailor therapy to individual patient needs, improving treatment outcomes and minimizing side effects.